Jensen C M, Pilegaard R, Hviid K, Nielsen J D, Nielsen H J
Department of Orthopaedic Surgery, Copenhagen County Hospital, University of Copenhagen, Gentofte, Denmark.
J Arthroplasty. 1999 Apr;14(3):312-8. doi: 10.1016/s0883-5403(99)90057-8.
Reinfusion of postoperative wound drainage blood has become an attractive alternative in primary total knee and hip arthroplasty. Quality of the drainage blood was studied with respect to content of extracellular bioactive substances and coagulation split products. Using the HandyVac ATS autotransfusion system, drainage blood was collected and reinfused within 6 hours postoperatively from 10 patients undergoing primary total knee arthroplasty. Blood samples were collected from the patients immediately after and 1 hour after opening of the tourniquet and after reinfusion of drainage blood. Samples were also collected from the drainage blood immediately before and at the end of reinfusion. The leukocyte-derived and platelet-derived bioactive substances histamine, eosinophil cationic protein (ECP), eosinophil protein X (EPX), myeloperoxidase (MPO), plasminogen activator inhibitor type 1 (PAI-1), and activated complement factor C3(C3a) and various coagulation factors and split products were analyzed in patient and drainage blood samples. None of the patients received additional predonated autologous blood or allogeneic blood components during the study period. Within 6 hours postoperatively, 250 to 1,000 mL drainage blood was collected and reinfused. Histamine, ECP, EPX, MPO, PAI-1, and C3a content was significantly increased in drainage blood immediately before and at the end of reinfusion. Reinfusion did not change the concentration of these substances in samples from the patients. Coagulation factors and various split products showed that drainage blood was defibrinated. Reinfusion of drainage blood did not change the coagulative capacity of the patients. Drainage blood appears to be defibrinated and contains various extracellular leukocyte-derived and platelet-derived bioactive substances. Reinfusion does not change the coagulative capacity or the concentration of bioactive substances of patients.
术后伤口引流血回输已成为初次全膝关节和全髋关节置换术中一种有吸引力的选择。针对细胞外生物活性物质和凝血裂解产物的含量对引流血的质量进行了研究。使用HandyVac ATS自动输血系统,从10例接受初次全膝关节置换术的患者中收集术后6小时内的引流血并进行回输。在松开止血带后即刻、1小时后以及引流血回输后从患者采集血样。还在引流血回输前即刻和结束时从引流血中采集样本。对患者和引流血样本中的白细胞源性和血小板源性生物活性物质组胺、嗜酸性粒细胞阳离子蛋白(ECP)、嗜酸性粒细胞蛋白X(EPX)、髓过氧化物酶(MPO)、纤溶酶原激活物抑制剂1型(PAI-1)、活化补体因子C3(C3a)以及各种凝血因子和裂解产物进行了分析。在研究期间,没有患者接受额外的预存自体血或异体血成分。术后6小时内,收集并回输了250至1000 mL引流血。回输前即刻和结束时引流血中的组胺、ECP、EPX、MPO、PAI-1和C3a含量显著增加。回输并未改变患者样本中这些物质的浓度。凝血因子和各种裂解产物表明引流血已去纤维蛋白。引流血回输并未改变患者的凝血能力。引流血似乎已去纤维蛋白,并含有各种细胞外白细胞源性和血小板源性生物活性物质。回输不会改变患者的凝血能力或生物活性物质的浓度。